Efficacy of Pyrotinib Plus Capecitabine in HER2-positive MBC With Active Brain Metastases That Have Failed ADCs
To evaluate the efficacy and safety of pyrotinib plus capecitabine in HER2-positive breast cancer patients with active brain metastases that have failed ADCs
Metastatic Breast Cancer in the Brain
DRUG: pyrotinib plus capecitabine
Objective Response Rate of Intracranial Lesion (CNS-ORR) by investigator, CNS-ORR was defined as percentage of participants with CNS response assessed by the investigator according to RANO-BM criteria, 2 months
Clinica Benifit Rate of Intracranial Lesion(CNS-CBR) by investigator, CNS-CBR was defined as percentage of participants with CNS response assessed by the investigator according to RANO-BM criteria, 6 months|Disease Control Rate（DCR）by investigator, DCR was defined as percentage of participants with CNS response assessed by the investigator according to RANO-BM criteria, 6 months|Progression-Free Survival (PFS), PFS was defined as the time from first dose to first documented disease progression (PD) or death from any cause, whichever occurred first, 1.5 year
To evaluate the efficacy and safety of pyrotinib plus capecitabine in Human Epidermal Growth Factor Receptor 2（HER2）-positive breast cancer patients with active brain metastases that have failed Antibody Drug Conjugates（Fam-trastuzumab deruxtecan-nxki\[T-DXd\] or A1811), had received no local radiotherapy previously and have at least one measurable brain lesion according to response assessment in neuro-oncology (RANO)criteria.